NAV3 is a genetic determinant of myocardial recovery in dilated cardiomyopathy and attenuates cardiac fibrosis

26 August 2022 (08:00 - 19:30)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Naveen Pereira

Mayo Clinic, Rochester (United States of America)

4 More presentations in this session

Presentation thumbnail

Increased Tenascin-C expression contributes to cardiac dysfunction and fibrosis in Duchenne muscular dystrophy

Associate Professor A. Kiss (Vienna, AT)

Abstract Slides Video

Presentation thumbnail

Desmoglein 2 mutant mice reproduce arrhythmogenic right ventricular cardiomyopathy patients' phenotype

Doctor S. Ohno (Suita, JP)

Abstract Slides Video

Presentation thumbnail

The role of the atrium in the development of the Takotsubo Syndrome - investigation of a patient-specific atrial stem cell model

Doctor K. Streckfuss-Boemeke (Wuerzburg, DE)

Abstract Slides Video

Presentation thumbnail

Dysferlin facilitates the de novo biogenesis of tubular membranes in hypertrophic remodelling

Ms N. Paulke (Goettingen, DE)

Abstract Slides Video

Access the full session

Session thumbnail

Pathophysiological mechanisms in cardiomyopathies and hypertrophic remodeling

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

You may be interested in

Congress Presentation

NAN-CS101: A first-in-human Phase 1 open-label dose-escalation study of AB-1002 gene therapy for the treatment of NYHA class III heart failure

Congress Presentation

Characterisation of the novel SCN5A-P1891A variant, implicated in left ventricular noncompaction cardiomyopathy in a Finnish family, using human induced pluripotent stem cell-derived cardiomyocytes.

Congress Presentation

ESC William Harvey Lecture in Basic Science - Q&A

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources